This network meta-analysis was the first study using appropriate statistical methods to provide indirect comparison for the currently available EGFR-TKIs (erlotinib, gefitinib, afatinib and icotinib) in treating patients with advanced NSCLC who harbor EGFR mutations, based on all available information from phase III randomized trials. This evidence concerns the gene EGFR and non-small cell lung carcinoma.